Cargando…

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece

BACKGROUND: To undertake an economic evaluation of rivaroxaban relative to the standard of care for stroke prevention in patients with non-valvular atrial fibrillation (AF) in Greece. METHODS: An existing Markov model designed to reflect the natural progression of AF patients through different healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kourlaba, Georgia, Maniadakis, Nikos, Andrikopoulos, George, Vardas, Panos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942277/ https://www.ncbi.nlm.nih.gov/pubmed/24512351 http://dx.doi.org/10.1186/1478-7547-12-5

Ejemplares similares

Economic evaluation of trimetazidine in the management of chronic stable angina in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

The disease burden of chronic obstructive pulmonary disease in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Self-reported prevalence of atherothrombosis in a general population sample of adults in Greece; A telephone survey
por: Maniadakis, Nikos, et al.
Publicado: (2011)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
por: Jacobs, Maartje S., et al.
Publicado: (2017)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
por: Ahrens, Ingo, et al.
Publicado: (2014)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
por: Shim, Jaemin, et al.
Publicado: (2021)

Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components
por: Stafylas, Panagiotis, et al.
Publicado: (2015)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
por: Fragoulakis, Vasilis, et al.
Publicado: (2015)

Rivaroxaban in atrial fibrillation cardioversion: an update
por: Lavalle, Carlo, et al.
Publicado: (2019)

A systematic review of the effectiveness of taxes on nonalcoholic beverages and high-in-fat foods as a means to prevent obesity trends
por: Maniadakis, Nikolaos, et al.
Publicado: (2013)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece
por: Fragoulakis, V, et al.
Publicado: (2013)

Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
Publicado: (2010)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2016)

Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation
por: Koge, Junpei, et al.
Publicado: (2022)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Physicians' Perceptions and Adherence to Guidelines for the Management of Hypertension: A National, Multicentre, Prospective Study
por: Theodorou, Mamas, et al.
Publicado: (2012)

Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study
por: Hanon, Olivier, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ifchgsh80ngcqleidn2k3p4olb